Key statistics
On Monday, Emergent BioSolutions Inc (EBS:NYQ) closed at 6.06, 326.76% above the 52 week low of 1.42 set on Feb 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.56 |
---|---|
High | 6.56 |
Low | 6.00 |
Bid | 6.01 |
Offer | 6.07 |
Previous close | 6.55 |
Average volume | 1.82m |
---|---|
Shares outstanding | 54.02m |
Free float | 52.87m |
P/E (TTM) | -- |
Market cap | 353.83m USD |
EPS (TTM) | -11.24 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 21:10 BST.
More ▼
- Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation
- Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
- Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
- Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
- Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions
- Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals
- Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa
- Emergent BioSolutions Reports Second Quarter 2024 Financial Results
- Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
- Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
More ▼